Disease biology · Drug mechanisms · Trial data · Competitive landscape · Investment implications
Cross-Trial Comparison Caveats
Different patient populations, baseline severity, geographies, and placebo rates across trials. Icotyde maintenance is responder-enriched (not ITT NRI). Bimzelx ~1yr is OC from pooled OLE. Head-to-head data only for select pairs. Biology diagrams simplified for clarity. All data from Phase 3 pivotals.
Sources: NEJM, Lancet, JAAD, Nature Reviews Immunology, Frontiers in Immunology, FDA labels · Updated March 2026